ES2332137T3 - Producto que comprende al menos un inhibidor de fosfatasa cdc25 en asociacion con al menos otro agente anticanceroso. - Google Patents

Producto que comprende al menos un inhibidor de fosfatasa cdc25 en asociacion con al menos otro agente anticanceroso. Download PDF

Info

Publication number
ES2332137T3
ES2332137T3 ES04767442T ES04767442T ES2332137T3 ES 2332137 T3 ES2332137 T3 ES 2332137T3 ES 04767442 T ES04767442 T ES 04767442T ES 04767442 T ES04767442 T ES 04767442T ES 2332137 T3 ES2332137 T3 ES 2332137T3
Authority
ES
Spain
Prior art keywords
radical
alkyl
representing
amino
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04767442T
Other languages
English (en)
Spanish (es)
Inventor
Gregoire Prevost
Marie-Christine Brezak Pannetier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Ipsen Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma SAS filed Critical Ipsen Pharma SAS
Application granted granted Critical
Publication of ES2332137T3 publication Critical patent/ES2332137T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES04767442T 2003-06-25 2004-06-24 Producto que comprende al menos un inhibidor de fosfatasa cdc25 en asociacion con al menos otro agente anticanceroso. Expired - Lifetime ES2332137T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0307649A FR2856688B1 (fr) 2003-06-25 2003-06-25 PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR0307649 2003-06-25

Publications (1)

Publication Number Publication Date
ES2332137T3 true ES2332137T3 (es) 2010-01-27

Family

ID=33515382

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04767442T Expired - Lifetime ES2332137T3 (es) 2003-06-25 2004-06-24 Producto que comprende al menos un inhibidor de fosfatasa cdc25 en asociacion con al menos otro agente anticanceroso.

Country Status (14)

Country Link
US (3) US20060281736A1 (cg-RX-API-DMAC7.html)
EP (3) EP1641453B1 (cg-RX-API-DMAC7.html)
JP (2) JP2007514639A (cg-RX-API-DMAC7.html)
AR (2) AR044930A1 (cg-RX-API-DMAC7.html)
AT (1) ATE439836T1 (cg-RX-API-DMAC7.html)
CA (1) CA2530668A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004022674D1 (cg-RX-API-DMAC7.html)
DK (1) DK1641453T3 (cg-RX-API-DMAC7.html)
ES (1) ES2332137T3 (cg-RX-API-DMAC7.html)
FR (1) FR2856688B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06000216A (cg-RX-API-DMAC7.html)
MY (1) MY141725A (cg-RX-API-DMAC7.html)
PL (1) PL1641453T3 (cg-RX-API-DMAC7.html)
WO (1) WO2005000852A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
ATE368654T1 (de) * 2001-12-27 2007-08-15 Sod Conseils Rech Applic Benzothiazol- und benzoxazol-4,7-dionderivate und ihre verwendung als cdc25-phosphatasen- inhibitoren
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
DE10353792A1 (de) 2003-11-13 2005-06-23 Exner, Heinrich, Dr.med.vet. Heil- und Wundsalbe auf der Basis einer wässrigen Emulsion
FR2877667B1 (fr) * 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) * 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
FR2879460B1 (fr) * 2004-12-17 2007-02-23 Sod Conseils Rech Applic Associations anti-douleur comprenant un derive de dihydroimidazopyrazine
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
ES2366874T3 (es) * 2007-09-06 2011-10-26 Basf Se Mezclas de poliariléteres ramificados y polímeros hidrófilos.
WO2009100375A1 (en) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
UY32776A (es) 2009-07-09 2011-02-28 Irm Llc Compuestos de imidazopirazinas sustituidas para el tratamiento de enfermedades parasitarias,composiciones farmacéuticas que los contienen y aplicación.
EP2786755A3 (en) 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
CN110691597A (zh) 2017-04-24 2020-01-14 诺华股份有限公司 2-氨基-1-(2-(4-氟苯基)-3-(4-氟苯基氨基)-8,8-二甲基-5,6-二氢咪唑并[1,2-a]吡嗪-7(8H)-基)乙酮及其组合的治疗方案
US20210106567A1 (en) * 2019-10-01 2021-04-15 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods for inhibiting carp-1 binding to nemo
CA3158733A1 (en) 2019-11-21 2021-05-27 Pilar Calvo Methods of treating small cell lung cancer with lurbinectedin formulations
US11981645B1 (en) 2023-10-10 2024-05-14 King Faisal University N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as antimicrobial compound

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US735674A (en) * 1902-01-29 1903-08-04 William C Matthias Sparking igniter for explosive-engines.
FR50000E (fr) 1938-11-29 1939-09-29 Moulin à café
US5523430A (en) * 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
US6383871B1 (en) * 1999-08-31 2002-05-07 Micron Technology, Inc. Method of forming multiple oxide thicknesses for merged memory and logic applications
PT1233787E (pt) * 1999-11-09 2005-04-29 Conseils Rech S Et D Applic Sc Produto contendo um inibidor da transducao dos sinais das proteinas g heterotrimericas em associacao com um outro agente anticanceroso para utilizacao terapeutica no tratamento do cancro
FR2812198B1 (fr) * 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
JP2004516297A (ja) * 2000-12-20 2004-06-03 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・(エス.セー.エール.アー.エス) サイクリン依存性キナーゼ(cdk)及びグリコーゲンシンターゼキナーゼ−3(gsk−3)の阻害剤
FR2825278A1 (fr) * 2001-05-30 2002-12-06 Sod Conseils Rech Applic Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
TW200304375A (en) * 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
ATE368654T1 (de) * 2001-12-27 2007-08-15 Sod Conseils Rech Applic Benzothiazol- und benzoxazol-4,7-dionderivate und ihre verwendung als cdc25-phosphatasen- inhibitoren
FR2834289B1 (fr) * 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2856686A1 (fr) * 2003-06-25 2004-12-31 Sod Conseils Rech Applic Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
JP4273056B2 (ja) * 2004-08-12 2009-06-03 不二越機械工業株式会社 研磨装置

Also Published As

Publication number Publication date
AR044930A1 (es) 2005-10-12
DE602004022674D1 (de) 2009-10-01
MY141725A (en) 2010-06-15
WO2005000852A3 (fr) 2005-06-30
EP1641453B1 (fr) 2009-08-19
EP1792905A1 (fr) 2007-06-06
FR2856688A1 (fr) 2004-12-31
WO2005000852A2 (fr) 2005-01-06
AR070977A2 (es) 2010-05-19
JP2009149694A (ja) 2009-07-09
FR2856688B1 (fr) 2008-05-30
MXPA06000216A (es) 2006-04-11
CA2530668A1 (fr) 2005-01-06
EP2335702A1 (fr) 2011-06-22
US20060281736A1 (en) 2006-12-14
US20090253685A1 (en) 2009-10-08
DK1641453T3 (da) 2009-12-14
PL1641453T3 (pl) 2010-01-29
US20090137596A1 (en) 2009-05-28
EP1641453A2 (fr) 2006-04-05
JP2007514639A (ja) 2007-06-07
ATE439836T1 (de) 2009-09-15

Similar Documents

Publication Publication Date Title
US20090137596A1 (en) G-protein inhibitor
AU2009231885B2 (en) Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use
ES2505270T3 (es) Inhibidores de JAK2 y su uso para el tratamiento de enfermedades mieloproliferativas y cáncer
AU2009298008B2 (en) Pyrazolo pyridine derivatives as NADPH Oxidase inhibitors
JP6181862B2 (ja) ピラゾロピロリジン誘導体および疾患の処置におけるその使用
US20090131428A1 (en) Benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors
EP2594555B1 (en) HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR
NZ551468A (en) Polycyclic agents for the treatment of respiratory syncytial virus infections
ES2689325T3 (es) Derivados de carbamoilo de carbonilamino-pirazoles bicíclicos como pro-fármacos
ES2331199T3 (es) Inhibidores de fosfatasas cdc25.
US7495021B2 (en) Benzothiazole- and benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors
MXPA06000217A (es) Benzotiazol-4,7-dionas y benzoxazol-4,7-dionas con sustituyentes en la posicion 5 o 6 y procedimiento para su preparacion.
CN121985947A (zh) 用于治疗银屑病、特应性皮炎或鱼鳞病的trex2的1,2,4-三唑-3-硫酮抑制剂
AU2013231140A1 (en) Polycyclic agents for the treatment of respiratory syncytial virus infections
HK1147741B (en) Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use